Amicus Shares Fall on Drug Failure in Fabry Disease Study
Amicus Therapeutics Inc. (FOLD) shares fell the most ever after the company said its experimental treatment for Fabry disease failed in a clinical trial.
Amicus dropped 47 percent to $3.06 at 4 p.m. New York time, the biggest one-day drop since it began trading in 2007. Amicus, based in Cranbury, New Jersey, is developing the treatment with London-based drugmaker GlaxoSmithKline Plc. (GSK) The shares have fallen 11 percent this year.
Fabry disease is a rare genetic disorder in which patients can’t break down fats that accumulate in the body’s organs. A six-month result from the 67-patient trial showed that the experimental drug didn’t perform better than a placebo, Amicus and Glaxo said today in a statement. The study, in the third and final stage of testing typically required for regulatory approval, will continue for a full year, the companies said.
No serious adverse events were reported in the clinical trial, the companies said.
To contact the reporters on this story: Elizabeth Lopatto in New York at elopatto@bloomberg.net; Drew Armstrong in New York at darmstrong17@bloomberg.net
To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net
Rate this Page
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.